Search Results

INVESTING IN THE BEST: OUR 2015 OPERATING GRANT WINNERS

We only invest in the best research. But how do we choose? How do we predict which research project is the most promising hope for the future? The answer is peer review—a tried...

NEW RESEARCH BEGINNINGS: MAKING IDEAS INTO REALITY

July is a month of new beginnings. At Fighting Blindness Canada, July 1st marks the start of a new research year. While our nation was celebrating Canada Day, we were also celebrating the...

CAN VALPROIC ACID (VPA) BE USED TO TREAT RETINITIS PIGMENTOSA? THE ANSWER IS IN THE GENE

Although winning a research award can help motivate scientists, Ruanne Lai doesn’t need extra motivation. For Ruanne, science is a “way of life” rather than simply a job. Ruanne’s recent win, however,...

VALPROIC ACID AS A TREATMENT FOR RETINITIS PIGMENTOSA

Clinical trials of valproic acid for the treatment of retinitis pigmentosa began in both the USA and Korea in late 2011. As well, a smaller shorter open-label trial was begun in Japan....

EYELEA APPROVED TO TREAT WET AMD IN CANADA

An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc....

VALPROIC ACID: THE PERILS OF USING DRUGS OFF-LABEL

Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa...